Modality
Fusion Protein
MOA
KRASG12Ci
Target
MET
Pathway
PD-1/PD-L1
MG
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
Mar 2021
→ Oct 2025
Phase 1Current
NCT08929654
1,898 pts·MG
2021-03→2025-10·Terminated
1,898 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-225mo agoPh2 Data· MG
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2025-10-22 · 5mo ago
MG
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08929654 | Phase 1/2 | MG | Terminated | 1898 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ | |
| Niralucimab | Ionis | Phase 1 | ALK |